Market Overview

Must Watch Stocks for January 3, 2017

Share:
Must Watch Stocks for January 3, 2017
Related OPK
Lightning Round: Jim Cramer Gives His Opinion On Lowe's Companies, Blackstone And More
51 Biggest Movers From Yesterday
Related CDTI
32 Stocks Moving In Wednesday's Pre-Market Session
28 Stocks Moving In Monday's Pre-Market Session

Some of the stocks that may grab investor focus today are:

  • Sprague Resources LP (NYSE: SRLP) agreed to acquire natural gas and electricity business from Global Partners LP for around $17.3 million. Sprague Resources shares gained 0.36 percent to close at $28.10 on Friday.
  • Shares of Innocoll Holdings PLC (NASDAQ: INNL) tumbled over 61 percent Friday after the company disclosed that it has received a Refusal to File letter from the FDA related to XARACOLL New Drug Application. Innocoll shares dipped 61.02 percent to close at $0.690 on Friday.
  • SM Energy Co (NYSE: SM) agreed to sell its non-operated Eagle Ford assets for $800 million. SM Energy shares fell 0.66 percent to close at $34.48 on Friday.

Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • Marinus Pharmaceuticals Inc (NASDAQ: MRNS) shares surged around 21 percent Friday as the company disclosed that ganaxolone has received Orphan Drug designation for the treatment of Fragile X Syndrome. Marinus Pharma shares gained 20.96 percent to close at $1.01 on Friday.
  • Clean Diesel Technologies, Inc. (NASDAQ: CDTI) disclosed that it has files for offering of common stock up to 6.23 million shares by selling stockholders. Clean Diesel Technologies shares dropped 2.27 percent to close at $2.15 on Friday.
  • KKR & Co. L.P. (NYSE: KKR) is said to still be interested in acquiring Depomed Inc (NASDAQ: DEPO) and would combine it with Arbor Pharmaceuticals, according to sources as reported by the New York Post on Friday. Depomed has set Wednesday as the deadline for final bids, the sources said. Depomed shares gained 2.44 percent to close at $18.02 on Friday.
  • Shares of Opko Health Inc. (NASDAQ: OPK) dropped around 19 percent Friday after the company reported disappointing results to a clinical trial. In a press release, Opko Health announced data analysis from a Phase 3 trial which evaluated its long-acting human growth hormone product (hGH-CTP) in adults with growth hormone deficiency (GHD). Opko Health shares fell 18.85 percent to close at $9.30 on Friday.

Posted-In: Stocks To WatchNews Pre-Market Outlook Markets Trading Ideas

 

Related Articles (CDTI + DEPO)

View Comments and Join the Discussion!

Partner Center